

Q3 2026

EARNINGS PRESENTATION

November 3, 2026

Chemours™

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our to be filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Third Quarter 2026 Highlights

Generated $1.5B in Net Sales and $200M in Adjusted EBITDA, supported by a ~10% increase in YoY TT pricing, paired with positive product mix shift in APM

APM Performance Solutions net sales grew 26% YoY, underscoring momentum and mix shift towards high-value end markets for APM products

Announced settlement with State of North Carolina and 11 local entities over Fayetteville Works discharges and unrelated PFAS claims, including AFFF use

Launched Chemours' liquid cooling portfolio, including four two-phase direct-to-chip and one immersion cooling fluid under the Faizeon™ brand

Completed the sale of the Kuan Yin property for total net consideration of ~$340 million, including the remaining land parcel for $56 million of gross proceeds

Third Quarter 2026 Financial Summary

($ in millions unless otherwise noted; excludes per share amounts)

	3Q26	3Q25	Y-o-Y Δ	2Q26	Q-o-Q Δ
Net Sales	**$1,540**	**$1,495**	**$45**	**$1,591**	**($51)**
Net (Loss) / Income[1]	$196	$46	$150	($274)	$470
Adj. Net Income [2]	$31	$26	$5	$64	($33)
EPS [3]	**$1.29**	**$0.31**	**$0.98**	**($1.81)**	**$3.10**
Adj. EPS [2,3]	**$0.21**	**$0.17**	**$0.04**	**$0.42**	**($0.21)**
Adj. EBITDA [2,4]	**$200**	**$189**	**$11**	**$247**	**($47)**
Operating Cash Flow	$149	$146	$3	$158	($9)
Capex	($51)	($41)	($10)	($44)	($7)
Free Cash Flow	**$98**	**$105**	**($7)**	**$114**	**($16)**
FCF Conversion	49%	56%	(7%)	46%	3%

1 Net (Loss) / Income attributable to The Chemours Company.


2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

3 Calculation based on diluted share count.

4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

Adjusted EBITDA Bridge: 3Q26 versus 3Q25

($ in millions)




Price Impacts: $79 million due to higher pricing across the three primary segments, with strength in TiO2 pricing tied to the three disclosed pricing actions since December of 2025, paired with mix shift towards higher value Performance Solutions products within APM.
Volume Impacts: ($25) million due to lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q3 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act
Cost/Other: ($39) million primarily driven by inflationary pressures experienced across the portfolio, partially offset by global net cost reduction efforts.
Currency: ($4) million primarily driven by unfavorable currency dynamics within the APM and TSS business units.

See reconciliation of Non-GAAP measures in the Appendix


Quarterly Segment Summary

($ in millions unless otherwise noted)

Net Sales




Adjusted EBITDA and Margin (%)



Liquidity Position as of September 30, 2026

($ in millions unless otherwise noted)

Total Liquidity [8]	$1.7B
Gross Debt	$3.9B
Net Debt [9]	$3.2B
TTM Net Leverage [10]	4.3x



5 Total cash balances include $103 million and $53 million of restricted cash and restricted cash equivalents on Chemours' Balance Sheets as of September 30, 2026 and December 31, 2025, respectively. Restricted cash of $52 million at the end of the second quarter was related to the MOU Escrow and $103 million at the end of the third quarter reflected primarily the PFAS Insurance Escrow as will be further described in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026

6 Operating cash flows for the third quarter of 2026 were $149 million, which includes the aforementioned receipt of $150 million in restricted cash related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by an approximate $100 million use of restricted cash to fund settlement payments associated with the 2025 settlement with the State of New Jersey and approximate $30 million of taxes related to the property sale in Kuan Yin.

7 Cash to shareholders reflects approximately $13 million in dividends paid to shareholders during the third quarter of 2026.

8 Total liquidity is calculated as the sum of $698 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030, and $220 million that expired on October 7, 2026.

9 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents.

10 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA.



STRATEGIC PROGRESS

PATHWAY TO THRIVE

Our Strategy

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long-Term
❑Manufacturing excellence as a basis for success	❑Investing smartly in selected growth projects	❑Holistic portfolio analysis focused on distinct value creation metrics	❑Measurable progress on resolving legacy liabilities in the interest of stakeholders
❑Improved and standardized operating model for consistent execution	❑Commercial effectiveness to drive sales growth	❑Shift product mix to higher value applications in growing end markets	❑Responsible manufacturing practices
❑Continuous improvement to adapt to changing markets	❑Innovation and new product development	❑Optimize asset footprint	❑Targeted policy efforts
>$250M cost reduction from 2024 to 2027	>5% Sales CAGR from 2024 to 2027	Driving shareholder value	Recognizing criticality of our chemistries

Balanced & Disciplined Capital Allocation To Create Shareholder Value

Expanding Free Cash Flow Conversion & Long-Term Objective of Net Leverage Below 3x Across Economic Cycles

Progress Achieved to Date

PATHWAY TO THRIVE

Operational Excellence

- ✓ Notable progress against the $250M of run-rate savings by end of 2027 across all areas of the company
- ✓ Advanced the Chemours Business System rollout, embedding Lean principles to drive continuous improvement in safety, quality, and reliability
- ✓ Executed a long-term chlorine supply agreement with Olin Corporation, supporting the long-term competitiveness of the DeLisle TiO2 site

Enabling Growth

- ✓ Launched Chemours' liquid cooling portfolio, including four two-phase direct-to-chip and one immersion cooling fluid under the Faizeon™ liquid cooling brand
- ✓ Continued sales in high-growth semiconductor and data center end markets approaching nearly half of APM Performance Solutions sales
- ✓ Realized approximately 10% of YoY pricing increase in TT in the third quarter of 2026 tied to previously announced pricing actions

Portfolio Management

- ✓ Progressed APM European asset review, through the announced exit of the Villers-St. Paul site
- ✓ Exited SPS Capstone™ business to prioritize higher return businesses and strengthen Chemours' overall portfolio
- ✓ Closed the sale of the former Kuan Yin TiO2 site in April 2026
- ✓ Shifted aspects of TT's mining operations to prioritize cash flow generation


Strengthening the Long-Term

- ✓ Announced settlement with State of North Carolina and 11 local entities over Fayetteville Works discharges and unrelated PFAS claims
- ✓ Reached a settlement with the EPA & WVDEP to resolve alleged permitting violations across three Chemours sites
- ✓ Settled with the State of New Jersey to resolve all environmental claims, including PFAS statewide
- ✓ Reduced fluorinated organic chemical (FOC) process emissions to air and water by 80% since 2018
- ✓ Addressed $2B+ of near-term debt maturities in the past 12 months

Balanced & Disciplined Capital Allocation: Completed the sale of the Kuan Yin site for ~$340M of net consideration, positioning the Company to paydown €280M of outstanding debt, and helping to progress towards the long-term goal of below 3x net leverage

Introducing: Faizeon™

Two-phase Liquid Cooling Fluids



Powering the next phase of liquid cooling.

Faizeon™ two-phase liquid cooling solutions harness the power of phase change to meet the ever-rising cooling demands of AI—delivering **superior performance with dramatically lower energy and water use.**

Performance

Superior heat transfer using a fraction of the energy and water—while reducing total cost of ownership.

Confidence

Backed by 90+ years of thermal-management expertise and purpose-built for two-phase direct-to-chip and immersion cooling.

Ecosystem

Built to support the full liquid cooling value chain and scale two-phase cooling responsibly.

Faizeon™ 100	Faizeon™ 110	Faizeon™ 200	Faizeon™ 220	Faizeon™ 500
Retrofit deployments Lowest-pressure profile Thin cold-plate compatibility	Low-pressure direct-to-chip Intermediate boiling point Strong material compatibility	Performance / environmental balance Medium-pressure operation High-density AI and HPC	Maximum thermal performance Advanced AI clusters High-density GPU environments	Two-phase immersion cooling Extreme AI workloads Nonflammable, near-zero water use

Strengthening the Long-Term: Resolving Legacy Liabilities
Continued Progress

2017:

1st Ohio MDL Settlement ($670.7M)

January 2021:

MOU with Corteva, EID, DuPont and Chemours on PFAS Liabilities: Created $4B cost sharing arrangement

2nd Ohio MDL Settlement ($83M)

June 2023:

U.S. Public Water System Class Action Settlement ($1.185B) Reached

Note: Finalized in Q2 2024

December 2024:

3rd Ohio MDL Settlement with Closure of MDL ($58.5M)

June 2026:

Announced Settlement with EPA/WVDEP: $22.5M civil penalty and $90M for site-specific mitigation projects over 15 years



February 2019:

Consent Order with NCDEQ for Fayetteville Works

July 2021:

Delaware NRD Settlement ($50M + $25M supplement)

November 2023:

Ohio NRD Settlement Reached ($110M)

July/August 2025:

Hoosick Falls Settlement ($27M)
NJ Settlement ($875M; ~$500M NPV)
Insurance Proceeds MOU

September 2026:

NC Settlement Announced with the state AG & 11 local entities ($455M; ~$360M NPV)

NC Settlement Overview

- Resolves litigations brought by the State of North Carolina ($75M) and 11 local entities ($380M) relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contamination unrelated to that site ($18M of the $455M settlement); Chemours' $180M NPV obligation is covered by existing accruals
- For purposes of the MOU, all future settlements with payment overtime are to be considered over a 25-year period at a 8% discount rate and MOU escrow contributions by MOU parties are no longer required under the agreement

Priorities for Resolving Remaining Legacy Matters

1. Opt out water system claims that involve costs to abate or meet regulatory requirements
2. Governmental-related claims, including regulatory agencies and State AGs (may arise in both regulatory process and litigation proceedings (state NRD matters))
3. Personal injury claims
4. Property-related claims, primarily involving loss of value



FOURTH QUARTER

GUIDANCE


Fourth Quarter and Full Year 2026 Guidance

Sequential Business Outlook:

Fourth Quarter 2026 Outlook

- **Consolidated**
  - Net Sales: Expected to decrease in the (10%) to (5%) range sequentially
  - Adjusted EBITDA: Expected to range between $160 million and $185 million
  - Corporate Expenses: Expected to range between $40 million and $45 million
  - Capital Expenditures: Expected to range between $75 million and $85 million
  - Free Cash Flows: Reflecting a source of cash
- **TSS**
  - Net Sales: Expected to decrease in the low-twenties to high-teens percentage range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere.
  - Adjusted EBITDA: Expected to approximate $105 million to $115 million, primarily driven by the referenced seasonality.
- **TT**
  - Net Sales: Expected to decrease in the low-teens to high-single digits percentage range, driven by traditional coatings season seasonality in the North American architectural paints market.
  - Adjusted EBITDA: Expected to range between $60 million and $65 million, driven by the referenced seasonality and sales timing.
- **APM**
  - Net Sales: Expected to increase in the low-to-mid teens percentage range, driven by continued strength in the Performance Solutions order book.
  - Adjusted EBITDA: Expected to be between $40 million and $45 million, driven by the referenced order book strength.

Full Year 2026 Outlook




11. Free Cash Flow Conversion includes receipt of $150 million related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by legal settlement payments in the year related to the finalization of the JCO with the State of New Jersey and the announced settlement with the State of North Carolina during the third quarter of 2026 as well as the taxes associated with the, now completed, Kuan Yin property sale.

APPENDIX




TSS Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)
% of total Net Sales



($ in millions)




Net Sales: The 9% year-over-year decrease was driven by a 9% decrease in volumes and a slight decrease in price. The decrease in volumes was primarily attributable to lower North American stationary AC aftermarket sales of TSS Opteon™ blends compared with elevated demand in the prior-year quarter, which benefited from the initial aftermarket channel fill associated with the stationary AC technology transition under the U.S. AIM Act.


Adjusted EBITDA: The decrease reflects the lower Opteon™ stationary aftermarket sales noted above and higher costs incurred during the period.

TT Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)



($ in millions)




Net Sales: The increase was driven by a 10% increase in global pricing and a 1% increase in global volumes, partially offset by a slight currency headwind. Pricing increased across all regions in connection with recent pricing announcements, while global volume growth reflected strength in North America, Latin America, and APAC excluding China that more than offset lower volumes across EMEA and China.

Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by the global pricing strength noted above and higher volumes, partially offset by inflationary cost pressures.


APM Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)

% of total Net Sales



($ in millions)



Net Sales: The 8% increase was primarily driven by a 6% increase in price and a 2% increase in volume, partially offset by a slight currency headwind. Performance Solutions Net Sales increased 26%, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets.

Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by a favorable mix shift toward higher-value Performance Solutions products serving data center and semiconductor end markets, partially offset by higher costs incurred during the period.

Segment Net Sales (Unaudited)

	2024				2025				2026		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Net sales by product group and segment											
Opteon™ refrigerants	$ 200	$ 227	$ 205	$ 178	$ 279	$ 375	$ 368	$ 243	$ 313	$ 337	$ 287
Freon™ refrigerants	173	173	146	124	97	123	98	113	162	150	100
Foam, propellants, and other	81	119	117	88	90	99	94	88	93	104	123
Total Thermal & Specialized Solutions	454	519	468	390	466	597	560	444	568	591	510
Titanium Dioxide	562	643	642	598	575	629	591	534	541	639	650
Minerals & Other	30	33	30	34	22	28	21	27	18	22	30
Total Titanium Technologies	592	676	672	632	597	657	612	561	559	661	680
Advanced materials	190	212	214	191	178	214	190	172	143	184	184
Performance solutions	113	133	140	133	116	132	121	141	100	142	153
Total Advanced Performance Materials	303	345	354	324	294	346	311	312	243	326	337
Performance chemicals and intermediates	14	13	14	13	11	15	12	12	11	13	13
Total Other Segment	14	13	14	13	11	15	12	12	11	13	13
Total net sales	$ 1,363	$ 1,553	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591	$ 1,540

Segment Net Sales by Region (Unaudited)

	2024				2025				2026		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Net sales by geographic region											
North America:											
Thermal & Specialized Solutions	$ 271	$ 308	$ 256	$ 194	$ 233	$ 336	$ 316	$ 241	$ 326	$ 340	$ 268
Titanium Technologies	246	274	270	236	267	282	252	221	235	267	282
Advanced Performance Materials	124	133	130	112	111	125	110	131	95	140	143
Other Segment	9	10	9	7	8	10	7	7	7	7	8
Total North America	650	725	665	549	619	753	685	599	663	754	701
Asia Pacific:											
Thermal & Specialized Solutions	39	53	55	53	53	59	69	53	71	72	70
Titanium Technologies	147	178	171	161	105	125	122	114	77	124	138
Advanced Performance Materials	105	127	138	148	115	147	138	132	89	117	133
Other Segment	3	2	3	3	2	3	3	3	2	4	3
Total Asia Pacific	294	360	367	365	275	334	332	301	239	317	344
Europe, the Middle East, and Africa:											
Thermal & Specialized Solutions	92	103	98	69	98	112	87	84	97	97	87
Titanium Technologies	124	130	126	131	142	156	141	128	151	156	138
Advanced Performance Materials	63	72	70	53	56	60	52	40	52	57	52
Other Segment	2	1	2	2	1	2	2	2	2	2	2
Total Europe, the Middle East, and Africa	281	306	296	255	297	330	282	254	302	312	279
Latin America (1):											
Thermal & Specialized Solutions	52	55	59	74	82	90	88	66	74	82	85
Titanium Technologies	74	95	105	104	83	94	97	99	96	114	122
Advanced Performance Materials	11	13	16	11	12	14	11	10	7	12	9
Other Segment	—	—	—	1	—	—	—	—	—	—	—
Total Latin America	137	163	180	190	177	198	196	175	177	208	216
Total net sales	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591	$ 1,540

[1] LATAM includes Mexico.

Segment Net Sales & Adjusted EBITDA (Unaudited)

	2024				2025				2026		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Segment Net Sales											
Thermal & Specialized Solutions	$ 454	$ 519	$ 468	$ 390	$ 466	$ 597	$ 560	$ 444	$ 568	$ 591	$ 510
Titanium Technologies	592	676	672	632	597	657	612	561	559	661	680
Advanced Performance Materials	303	345	354	324	294	346	311	312	243	326	337
Other Non-Reportable Segment	14	13	14	13	11	15	12	12	11	13	13
Total Company Net Sales	$ 1,363	$ 1,553	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591	$ 1,540
Segment Adjusted EBITDA											
Thermal & Specialized Solutions	$ 150	$ 160	$ 139	$ 122	$ 141	$ 207	$ 194	$ 128	$ 190	$ 213	$ 136
Titanium Technologies	69	83	78	70	50	47	25	23	18	48	85
Advanced Performance Materials	30	45	38	47	32	50	14	12	5	26	24
Other Non-Reportable Segment	2	3	3	-	1	4	2	1	3	2	1
Corporate Expenses	(55)	(77)	(54)	(69)	(57)	(47)	(44)	(34)	(47)	(42)	(46)
Segment Adjusted EBITDA Margin											
Thermal & Specialized Solutions	33%	31%	30%	31%	30%	35%	35%	29%	33%	36%	27%
Titanium Technologies	12%	12%	12%	11%	8%	7%	4%	4%	3%	7%	13%
Advanced Performance Materials	10%	13%	11%	15%	11%	14%	5%	4%	2%	8%	7%
Other Non-Reportable Segment	14%	23%	21%	0%	9%	27%	17%	10%	27%	15%	8%

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2)

($ in millions except per share amounts)	Three Months Ended September 30,				Three Months Ended June 30,		Twelve Months Ended September 30,	
	2026		2025		2025		2026	2025
Cash flows (used for) provided by operating activities	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
(Loss) income before income taxes	$ 222		$ 38		$ (1)		$ 132	$ (290)
Net (loss) income attributable to Chemours	$ 196	$ 1.29	$ 46	$ 0.31	$ (274)	$ (1.79)	$ (154)	$ (350)
Non-operating pension and other post-retirement benefit income	(2)	(0.01)	(4)	(0.03)	(3)	(0.02)	(10)	(7)
Exchange losses, net	4	0.03	1	0.01	1	0.01	8	11
Restructuring, asset-related, and other charges	3	0.02	4	0.03	3	0.02	23	61
Goodwill impairment charge	—	—	—	—	—	—	—	—
Loss on extinguishment of debt	0	—	—	—	2	0.01	16	1
Gain on sales of assets and businesses, net	(50)	(0.33)	(7)	(0.05)	(266)	(1.74)	(316)	(8)
Transaction costs	—	—	—	—	—	—	6	4
Qualified spend recovery	(5)	(0.03)	(13)	(0.09)	(6)	(0.04)	(23)	(39)
Litigation-related (income) charges, net	(138)	(1)	8	0.05	225	1.47	126	301
Environmental charges	18	0.12	13	0.09	144	0.94	189	88
Adjustments made to income taxes	—	—	(18)	(0.12)	207	1.35	227	168
Provision for (benefit from) income taxes relating to reconciling items	5	0	(4)	(0.03)	31	0.20	18	(80)
Adjusted Net Income	$ 31	$ 0.21	$ 26	$ 0.17	$ 64	$ 0.42	$ 110	$ 150
Net income attributable to non-controlling interests	—		—		—		(1)	1
Interest expense, net	69		68		68		274	268
Depreciation and amortization	79		80		80		319	311
All remaining provision for income taxes	21		15		35		42	52
Adjusted EBITDA	$ 200		$ 189		$ 247		$ 744	$ 782

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2)

($ in millions except per share amounts)	Three Months Ended September 30,				Three Months Ended June 30,		Twelve Months Ended September 30,	
	2026		2025		2025		2026	2025
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Adjusted EBITDA	$ 200		$ 189		$ 247		$ 744	$ 782
Total debt principal							$ 3,872	$ 4,185
Less: Cash and cash equivalents							(698)	(613)
Total debt principal, net							$ 3,174	$ 3,572
Net Leverage Ratio (calculated using GAAP earnings)							24x	(12.3)x
Net Leverage Ratio (calculated using Non-GAAP earnings)							4.3x	4.6x
Weighted-average number of common shares outstanding - basic	151,330,846		150,320,265		151,225,044			
Weighted-average number of common shares outstanding - diluted	151,909,595		150,781,614		152,813,557			
Basic (loss) earnings per share of common stock (2)	$ 1.29		$ 0.31		$ (1.81)			
Diluted (loss) earnings per share of common stock (1) (2)	$ 1.29		$ 0.31		$ (1.81)			
Adjusted basic earnings per share of common stock (2)	$ 0.21		$ 0.17		$ 0.42			
Adjusted diluted earnings per share of common stock (1) (2)	$ 0.21		$ 0.17		$ 0.42			

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended June 30, 2026. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended September 30, 2026 and 2025, and the three months ended June 30, 2026 as Adjusted Net Income was in a net income position.

(2) Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

* Note: $ per share columns may not sum due to rounding.

GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation (1)

	Three Months Ended			Nine Months Ended	
	September 30,		June 30,	September 30,	
	2026	2025	2026	2026	2025
Cash flows provided by (used for) operating activities	$ 149	$ 146	$ 158	$ 263	$ 127
Less: Purchases of property, plant, and equipment	(51)	(41)	(44)	(144)	(168)
Free Cash Flows	$ 98	$ 105	$ 114	$ 119	$ (41)
Adjusted EBITDA	200	189	247	616	614
Free Cash Flow Conversion	49%	56%	46%	19%	(7)%

(1) Includes the receipt of $150 million related to the PFAS Insurance Proceeds MOU, in connection with the finalization of the JCO with the State of New Jersey, partially offset by approximately $100 million in related settlement payments in Q3 2026. See "Note 17 - Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements that will be included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.

2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1) (2)

	Estimated Year Ended December 31, 2026	
	Low	High
Cash flows provided by operating activities	$ 340	$ 390
Less: Purchases of property, plant, and equipment	(220)	(230)
Free Cash Flows	$ 120	$ 160
Adjusted EBITDA	775	800
Free Cash Flow Conversion	15%	20%

(1) Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.

(2) Includes the receipt of $150 million related to the PFAS Insurance Proceeds MOU, in connection with the finalization of the JCO with the State of New Jersey, partially offset by approximately $100 million in related settlement payments in the year.

2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)

	(Estimated) Year Ending December 31, 2026	
	Low	High
Net loss attributable to Chemours	$ (100)	$ (90)
Restructuring, transaction, and other costs, net (2)	210	210
Adjusted Net Income	110	120
Interest expense, net	275	280
Depreciation and amortization	320	320
All remaining provision for income taxes	70	80
Adjusted EBITDA	$ 775	$ 800

(1) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.

(2) Restructuring, transaction, and other costs, net includes all reconciling items from net loss attributable to Chemours to Adjusted Net Income, including income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.



Chemours™

® 2026 CHEMOURS. ALL RIGHTS RESERVED